Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus

Diabetic peripheral neuropathy is a common chronic complication of diabetes mellitus, significantly impairing well-being, quality of life and functioning of patients. The prevalence of diabetic peripheral neuropathy in the Russian Federation ranges from 0.1% to 67.2% in type 1 and from 0.1 to 42.4% in type 2 diabetes mellitus. However, based on the large-scale epidemiological studies, the true prevalence of diabetic peripheral neuropathy is much higher (50 to 70%), with its painful variant occurring in 16% to 30% of patients. Despite the fact that diabetic peripheral neuropathy remains the most common chronic complication of diabetes mellitus, its diagnosis and therapy leave much to be desired. To optimize diagnostic and treatment approaches to painful diabetic peripheral neuropathy, a group of experts representing the leading Russian professional medical associations has developed clinical guidelines for the diagnosis and rational therapy of patients with painful diabetic peripheral neuropathy.

This document presents practical aspects of the clinical diagnosis of painful diabetic peripheral neuropathy and an algorithm for differential diagnosis of pain in the lower extremities in patients with diabetes mellitus. The use of symptomatic analgesics with central action, such as anticonvulsants, antidepressants and opioids, is based on the main aspects of neuropathic pain pathophysiology. The characteristics of each drug class are given, with consideration of evidence on their efficacy, tolerability, and the possibility of combination therapy. The data on the first, second, and third lines of agents is presented in accordance with several international clinical guidelines. The need for a tailored drug choice, taking into account the evidence-based data on their efficacy and safety, concomitant drug therapy, tolerability, cost and preferences of the patient, age of the patient and concomitant disorders, is emphasized.

diabetes mellitus, diabetic peripheral neuropathy, painful neuropathy, neuropathic pain, diagnosis, treatment

1. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета // Сахарный диабет. — 2017. — Т. 20. — №1. — С. 13-41. [Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes mellitus. 2017;20(1):13-41. (In Russ.)] doi: https://doi.org/10.14341/DM8664

2. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 9-й выпуск // Сахарный диабет. — 2019. — Т. 22. — №1S. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. 9th edition. Diabetes mellitus. 2019;22(1S). (In Russ.)] doi: https://doi.org/10.14341/DM221S1

3. Болевые синдромы в неврологической практике. / Под ред. Вейна А.М. — М.; 2001. [Veyn AM, editor. Bolevye sindromy v nevrologicheskoy praktike. Moscow; 2001. (In Russ.)]

4. Hansson P, Fields H, Hill R, Marchettini P, editors. Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management. Seattle: IASP Press; 2001.

5. Яхно Н.Н., Давыдов О.С. Неврологическая боль. Современное состояние проблемы. В кн.: Болезни мозга – медицинские и социальные аспекты / Под ред. Е.И. Гусева, А.Б Гехт. — М.: Буки-Веди, 2016. — C.605–627. [Yakhno NN, Davidov OS. Neuropathic pain. The current state of the problem. In: Gusev EI, Gecht AB, editors. Brain Diseases - Medical and Social Aspects. Moscow: Buki-Vedi; 2011. p.605–627. (In Russ.)]

6. Боль. Практическое руководство для врачей. / Под ред. Яхно Н.Н. — М.: Издательство РАМН АНО, 2011. [Yakhno NN, editor. Pain. Practical guide for doctors. Moscow: RAMN ANO; 2011. (In Russ.)]

7. van Hecke O, Austin SK, Khan RA et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654-662. doi: https://doi.org/10.1016/j.pain.2013.11.013

8. DiBonaventura MD, Sadosky A, Concialdi K. The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey. J Pain Res. 2017;10:2525-2538. doi: https://doi.org/10.2147/JPR.S127014

9. Яхно Н.Н., Кукушкин М.Л., Давыдов О.С. Результаты российского эпидемиологического исследования распространенности невропатической боли, ее причин и характеристик в популяции амбулаторных больных, обратившихся к врачу-неврологу // Боль. — 2008. — №3. — С. 24-32. [Yakhno NN, Kukushkin ML, Davidov OS. Rezul'taty rossijskogo jepidemiologicheskogo issledovanija rasprostranennosti nevropaticheskoj boli, ee prichin i harakteristik v populjacii ambulatornyh bol'nyh, obrativshihsja k vrachu-nevrologu. Bol’. 2008;(3):24-32. (In Russ.)]

10. Яхно Н.Н., Кукушкин М.Л., Чурюканов М.В., Сыровегин А.В. Результаты открытого мультицентрового исследования «МЕРИДИАН» по оценке распространенности болевых синдромов в амбулаторной практике и терапевтических предпочтений врачей // Российский журнал боли. — 2012. — №3-4. — С. 10-14. [Yahno NN, Kukushkin ML, Churyukanov MV, Syrovegin AV. The results of open multicentral study "Meridian" for assessment of pain syndromes prevalence in ambulatory and therapeutic preferences of physicians. Russian journal of pain. 2012;(3-4):10-14. (In Russ.)]

11. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi: https://doi.org/10.2337/dc16-2042

12. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473. doi: https://doi.org/10.1007/s11910-014-0473-5

13. Dyck PJ, Albers JW, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620-628. doi: https://doi.org/10.1002/dmrr.1226

14. Biessels GJ, Bril V, Calcutt NA, et al. Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). J Peripher Nerv Syst. 2014;19(2):77-87. doi: https://doi.org/10.1111/jns5.12072

15. O’Brien PD, Hinder LM, Sakowski SA, Feldman EL. ER stress in diabetic peripheral neuropathy: A new therapeutic target. Antioxid Redox Signal. 2014;21(4):621-633. doi: https://doi.org/10.1089/ars.2013.5807

16. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573-583. doi: https://doi.org/10.1038/nrneurol.2011.137

17. Malik RA, Veves A, Tesfaye S, et al. Small fibre neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev. 2011;27(7):678-684. doi: https://doi.org/10.1002/dmrr.1222

18. Baron R, Tolle TR, Gockel U, et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain. 2009;146(1-2):34-40. doi: https://doi.org/10.1016/j.pain.2009.06.001

19. Freeman R, Baron R, Bouhassira D, et al. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain. 2014;155(2):367-376. doi: https://doi.org/10.1016/j.pain.2013.10.023

20. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21(9):976-982. doi: https://doi.org/10.1111/j.1464-5491.2004.01271.x

21. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7):1518-1522. doi: https://doi.org/10.2337/dc05-2228

22. Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10(2):393-400. doi: https://doi.org/10.1111/j.1526-4637.2008.00555.x

23. Vileikyte L, Leventhal H, Gonzalez JS, et al. Diabetic Peripheral Neuropathy and Depressive Symptoms: The association revisited. Diabetes Care. 2005;28(10):2378-2383. doi: https://doi.org/10.2337/diacare.28.10.2378

24. Vileikyte L, Rubin RR, Leventhal H. Psychological aspects of diabetic neuropathic foot complications: an overview. Diabetes Metab Res Rev. 2004;20 Suppl 1:S13-18. doi: https://doi.org/10.1002/dmrr.437

25. Vinik E, Silva MP, Vinik AI. Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):97-109, viii. doi: https://doi.org/10.1016/j.ecl.2010.12.008

26. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic Somatic Neuropathies. Diabetes Care. 2004;27(6):1458-1486. doi: https://doi.org/10.2337/diacare.27.6.1458

27. Perkins BA, Olaleye D, Zinman B, Bril V. Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic. Diabetes Care. 2001;24(2):250-256. doi: https://doi.org/10.2337/diacare.24.2.250

28. Tan LS. The clinical use of the 10g monofilament and its limitations: a review. Diabetes Res Clin Pract. 2010;90(1):1-7. doi: https://doi.org/10.1016/j.diabres.2010.06.021

29. Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31(8):1679-1685. doi: https://doi.org/10.2337/dc08-9021

30. Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry. 1983;46(6):491-499. doi: https://doi.org/10.1136/jnnp.46.6.491

31. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956-962. doi: https://doi.org/10.2337/diacare.28.4.956

32. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-2293. doi: https://doi.org/10.2337/dc10-1303

33. Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138(Pt 1):43-52. doi: https://doi.org/10.1093/brain/awu307

34. Старостина Е.Г. Диабетическая нейропатия: некоторые вопросы дифференциальной диагностики и системной терапии болевого синдрома // РМЖ. — 2017. — Т. 25. — №22. — С. 3-14. [Starostina EG. Diabetic neuropathy: some issues in differential diagnosis and systemic treatment of the pain syndrome. RMZh. 2017;25(22):2-14. (In Russ.)]

35. Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi: https://doi.org/10.1056/NEJM199309303291401

36. Diabetes Control and Complications Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 1995;38(6):869-880. doi: https://doi.org/10.1002/ana.410380607

37. Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: A randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism. 1996;45(12):1508-1513. doi: https://doi.org/10.1016/s0026-0495(96)90180-8

38. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-534. doi: https://doi.org/10.1016/s1474-4422(12)70065-0

39. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-430. doi: https://doi.org/10.1016/s0140-6736(10)60576-4

40. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117. doi: https://doi.org/10.1016/0168-8227(95)01064-k

41. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-430. doi: https://doi.org/10.1016/S0140-6736(10)60576-4

42. Charles M, Ejskjaer N, Witte DR, et al. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care. 2011;34(10):2244-2249. doi: https://doi.org/10.2337/dc11-0903

43. Charles M, Fleischer J, Witte DR, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia. 2012;56(1):101-108. doi: https://doi.org/10.1007/s00125-012-2744-5

44. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. doi: https://doi.org/10.1007/s11892-014-0528-7

45. Pop-Busui R, Lu J, Brooks MM, et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care. 2013;36(10):3208-3215. doi: https://doi.org/10.2337/dc13-0012

46. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. doi: https://doi.org/10.1056/NEJMoa021778

47. Balducci S, Iacobellis G, Parisi L, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216-223. doi: https://doi.org/10.1016/j.jdiacomp.2005.07.005

48. Singleton JR, Marcus RL, Jackson JE, et al. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014;1(10):844-849. doi: https://doi.org/10.1002/acn3.125

49. Carnethon MR, Prineas RJ, Temprosa M, et al. The Association Among Autonomic Nervous System Function, Incident Diabetes, and Intervention Arm in the Diabetes Prevention Program. Diabetes Care. 2006;29(4):914-919. doi: https://doi.org/10.2337/diacare.29.04.06.dc05-1729

50. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294-1299. doi: https://doi.org/10.2337/dc06-0224

51. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The «COMBO-DN study»--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616-2625. doi: https://doi.org/10.1016/j.pain.2013.05.043

52. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi: https://doi.org/10.1016/S1474-4422(14)70251-0

53. Приказ МЗ РФ от 30.06.2015 № 386н «О внесении изменений в приложения к приказу Министерства здравоохранения Российской Федерации от 20 декабря 2012 г. №1175н «Об утверждении порядка назначения и выписывания лекарственных препаратов, а также форм рецептурных бланков на лекарственные препараты, порядка оформления указанных бланков, их учета и хранения»». [Order of the Ministry of Health of the Russian Federation of 30 Jun 2015 № 386н «O vnesenii izmeneniy v prilozheniya k prikazu Ministerstva zdravookhraneniya Rossiyskoy Federatsii ot 20 dekabrya 2012 g. №1175n «Ob utverzhdenii poryadka naznacheniya i vypisyvaniya lekarstvennykh preparatov, a takzhe form retsepturnykh blankov na lekarstvennye preparaty, poryadka oformleniya ukazannykh blankov, ikh ucheta i khraneniya»». (In Russ.)]